Dose Equivalence Between Flixotide and Symbicort
Fluticasone propionate (Flixotide) and budesonide/formoterol (Symbicort) are not directly equivalent medications because Symbicort contains both an inhaled corticosteroid (budesonide) and a long-acting beta-agonist (formoterol), while Flixotide contains only fluticasone propionate. To establish equivalence, you must compare the corticosteroid components: fluticasone propionate versus budesonide.
Corticosteroid Potency Ratio
The potency ratio of fluticasone propionate to budesonide is approximately 2:1, meaning fluticasone is roughly twice as potent as budesonide 1. This is reflected in the NAEPP Expert Panel Report 3 dosing tables:
Low Daily Dose Equivalents (Adults):
- Fluticasone propionate: 88-264 mcg/day
- Budesonide: 180-600 mcg/day
Medium Daily Dose Equivalents (Adults):
- Fluticasone propionate: >264-440 mcg/day
- Budesonide: >600-1200 mcg/day
High Daily Dose Equivalents (Adults):
- Fluticasone propionate: >440 mcg/day
- Budesonide: >1200 mcg/day
Practical Conversion Examples
When converting from Flixotide to Symbicort, use these approximate equivalents based on the corticosteroid component:
- Flixotide 100 mcg ≈ Symbicort 200/6 mcg (budesonide 200 mcg)
- Flixotide 250 mcg ≈ Symbicort 400/12 mcg (budesonide 400 mcg)
- Flixotide 500 mcg ≈ Symbicort 800/24 mcg (budesonide 800 mcg)
Research confirms this ratio: a study comparing Flixotide Diskus and Pulmicort Turbuhaler found a potency ratio of 1.50:1 to 1.75:1 (95% CI 1.10:1-2.43:1) 2.
Important Clinical Considerations
The addition of formoterol in Symbicort provides bronchodilation that Flixotide alone does not offer. This means:
If switching from Flixotide monotherapy to Symbicort, you gain the benefit of a long-acting beta-agonist, which improves lung function, symptom control, and reduces exacerbations beyond what the corticosteroid alone provides 3, 4.
Symbicort is not simply a "replacement" for Flixotide—it represents step-up therapy combining anti-inflammatory and bronchodilator effects in a single inhaler 5, 6.
Clinical trials demonstrate that budesonide/formoterol combinations are more effective than higher doses of fluticasone alone for improving peak expiratory flow, symptom control, and reducing exacerbations 5.
Guideline-Based Approach
According to NAEPP guidelines 1, when patients require more than low-dose inhaled corticosteroids:
- Preferred approach: Add a long-acting beta-agonist to low-medium dose ICS (like switching from Flixotide to Symbicort)
- Alternative approach: Increase ICS dose alone (staying on Flixotide at higher dose)
The combination approach (Symbicort) is preferred over increasing corticosteroid dose alone because it provides superior efficacy with potentially lower corticosteroid exposure 3.
Common Pitfalls to Avoid
- Do not assume 1:1 equivalence—fluticasone is approximately twice as potent as budesonide
- Do not ignore the formoterol component—Symbicort provides additional bronchodilation that must be accounted for in your treatment plan
- Preparations are not interchangeable on a mcg-per-puff basis 1—always refer to established equivalency tables
- Monitor patient response clinically rather than relying solely on dose calculations, as individual responses vary 1